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home-made fenestrated atrial septal occluder
in 18-year-old with pulmonary hypertension
Hacer Kamali1, Turkay Saritas1,3*, Abdullah Erdem1, Celal Akdeniz2 and Volkan Tuzcu2Abstract
Background: Hemodynamically significant muscular ventricular septal defects in children after the infantile period
are a rare occurrence and ideal for transcatheter closure. In cases of severe concomitant pulmonary hypertension, it
may be necessary to fenestrate the device. In this report, we present an 18-year old patient with a large mid-
trabecular ventricular septal defect and severe pulmonary hypertension that underwent percutaneous closure of
the defect with a home-made fenestrated atrial septal occluder.
Case presentation: An 18-year-old female patient referred to us with complaints of dyspnea (NYHA score of 2–3).
Physical examination revealed an apical rumble and a harsh second heart sound. Echocardiographic examination
revealed a large mid-trabecular ventricular septal defect with bidirectional shunt and the widest diameter measuring
22 mm on 2D echocardiography. Left and right heart cavities were enlarged. Before and after the vasoreactivity test
performed during cardiac catheterization, average aortic pressure was 65→ 86 mmHg, average pulmonary artery
pressure: 58→ 73 mmHg, Qp/Qs: 1.6→ 3.2, PVR: 4.6→ 4.3 Wood/U/m2 and PVR/SVR: 0.5→ 0.2. On left-ventricular
angiocardiogram, the largest end-diastolic defect diameter was 21 mm. The closure procedure was performed with
transthoracic echocardiographic guidance, using a 24 mm Cera septal occluder and a 14 F sheath dilator to make a
4.5-5 mm opening. Measured immediately after the procedure and during cardiac catheterization one month later,
average aortic pressure was 75→ 75 mmHg, average pulmonary artery pressure: 66→ 30 mmHg, Qp/Qs 1.5→ 1.4,
PVR: 4.4→ 2.9 Wood/U/m2 and PVR/SVR: 0.4→ 0.2. Transthoracic echocardiographic examination performed
24 hours after the procedure showed a max 35–40 mmHg gradient between the left and right ventricles through
the fenestration. After the procedure, we observed sporadic early ventricular systoles and a nodal rhythm disorder
that started after approximately 12 hours and spontaneously reverted to normal 9 days later.
Conclusion: In patients with large ventricular septal defects, large atrial septal occluders may be used. In cases with
risk of pulmonary vascular disease, a safer option would be to close the defect using a manually fenestrated device.
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Hemodynamically significant muscular ventricular septal
defects (VSD) in children after the infantile period are a
rare occurrence and ideal for transcatheter closure [1]. De-
pending on the type, size, location and number of defects,
it may be necessary to use an off-label device or multiple* Correspondence: turkaysaritas@yahoo.com
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unless otherwise stated.devices [2-4]. Additionally, in cases of severe concomitant
pulmonary hypertension (PHT), it may be necessary to fen-
estrate the device [5]. In this report, we present an 18-year
old patient with a large mid-trabecular VSD and severe
PHT that underwent percutaneous closure of the defect
with a home-made fenestrated atrial septal occluder (ASO).
Case presentation
An 18-year-old female patient referred to us with com-
plaints of dyspnea (NYHA score of 2–3). An apical rumble
and a harsh second heart sound were heard in physical
examination. Echocardiographic examination revealed aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Diameters of VSD on transthoracic echocardiogram.
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http://www.biomedcentral.com/1471-2261/14/74large mid-trabecular VSD with bidirectional shunt and
the widest diameter measuring 22 mm on 2D echocar-
diography (ECHO) (Figure 1; Additional file 1). The de-
fect was located 9 mm proximal to the moderator band.
Left and right heart cavities were enlarged; left ventricle,
left atrium and right ventricle end-diastolic diameters
were respectively 68 mm (Z score: +8.23), 44 mm (Z
score: +6.22) and 41 mm (Z score: +10.3). Pulmonary
artery diastolic pressure, which we were able to measure
due to pulmonary insufficiency, was 58 mmHg. Before
and after the vasoreactivity test with inhaled iloprost per-
formed during cardiac catheterization, average aortic pres-
sure was 65→ 86 mmHg, average pulmonary artery
pressure: 58→ 73 mmHg, Qp/Qs: 1.6→ 3.2, PVR: 4.6→
4.3 Wood/U/m2 and PVR/SVR: 0.5→ 0.2 (Table 1).
On left-ventricular angiocardiogram, the largest end-
diastolic defect diameter was 21 mm. The closure proced-
ure was performed with transthoracic echocardiographic
guidance, using a 24 mm Cera septal occluder (CSO, Life-
tech Scientific Co., ltd, Shenzhen, China) and a 14 F sheath
dilator to make a 4.5-5 mm opening (Figures 2 and 3).
Measured immediately after the procedure and during car-
diac catheterization one month later, average aortic pres-
sure was 75→ 75 mmHg, average pulmonary artery
pressure: 66→ 30 mmHg, Qp/Qs 1.5→ 1.4, PVR: 4.4→
2.9 Wood/U/m2 and PVR/SVR: 0.4→ 0.2 (Table 1).
Transthoracic echocardiographic examination performed
24 hours after the procedure showed a max 35–40 mmHgTable 1 Hemodynamic parameters during the vasoreactivity te
Before vasoreactivity test After
Mean systemic pressure (mmHg) 65




PA: Pulmonary artery; Qp/Qs: Pulmonary to systemic flow ratio; PVR: Pulmonary vas
systemic vascular resistance ratio.gradient between the left and right ventricles through the
fenestration. At the follow-up examination one month later,
the gradient level was the same and there was a 50 drop in
pulmonary artery diastolic pressure compared to the pre-
procedure value.
The patient had a normal sinus rhythm prior to the pro-
cedure. After the procedure, we observed sporadic early
ventricular systoles and a nodal rhythm disorder that started
after approximately 12 hours and spontaneously reverted to
normal 9 days later. The patient was put on dexametha-
sone for the nodal rhythm. Propranolol was started after
Holter ECG showed intermittent non-sustained ventricular
tachycardia (VT) attacks. When the initially intermittent
nodal rhythm became permanent, the patient was switched
to sotalol. The last ECG and Holter ECG showed a normal
sinus rhythm with sporadic early ventricular systoles and
no VT attacks (Figures 4 and 5). Holter ECG performed
1 month later showed no early ventricular systoles.
The patient was closely monitored for hemolysis due
to the fenestration of the device, but none was observed.
The patient’s dyspnea (NYHA score 2–3 upon admis-
sion) started to recede on the 4-5th day after the procedure
and was graded as 1–2 in the follow-up examination
1 month later.
Discussion
Transcatheter closure of congenital and acquired VSDs is
a procedure that has gained widespread use in the recentst, immediately after the procedure and one month later






cular resistance; WU: Wood Unit; PVR/SVR: Pulmonary vascular resistance to
Figure 2 Fenestration procedure and the fenestrated ASD device.
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designed for atrial septal defects (ASD), but eventually spe-
cial devices intended for closure of muscular and perimem-
branous defects were developed [6,7]. Although there has
been remarkable progress in production of specifically de-
signed occlusion devices, demand for off-label or custom-
made devices suitable for various types of defects remains
high [2,3,8].
Transcatheter closure of postinfarction, traumatic or re-
sidual postoperative VSDs is mainly performed using ASOs
[3,9]. As ECHO and angiocardiographic measurements
showed a large defect size in our patient, we elected to use
a 24 mm ASO, a device 2–3 mm larger than the defect.
The defect could have been closed using a 24 mm muscular
VSD occluder or a post-myocardial infarction muscular
VSD occluder as well; however, we preferred the ASO as it
would allow for more convenient manual fenestration.
Long-term pulmonary hypertension may lead to a fixed
increase in pulmonary vascular resistance. In some patients
that have undergone VSD closure, pulmonary hypertension
may persist or regress very slowly, in which case there mayFigure 3 2D imaging of device after the procedure.be hypertensive crisis-like exacerbations requiring long-term
ventilation and specific treatment. In VSD cases with high
pulmonary resistance, post-operative pulmonary hyperten-
sive crises as well as acute congestive heart failure and re-
spiratory failure may prove fatal. For these reasons, surgeons
nowadays are instructed to leave an opening in the VSD
patch or to use a flap patch that allows for left-to-right
shunt [10]. For the same reasons, fenestration is now per-
formed on transcatheter occluder devices. Home-made fen-
estrated devices have been safely used in cases of ASD with
severe PHT under the assumption that fenestrated occluders
reduce left-to-right shunt and in the long run, lower pulmon-
ary arterial pressure [5]. Bruch et al. reported using a home-
made fenestrated ASO that allowed for a minor to moderate
bidirectional shunt in elderly patients with PHT and/or right
heart failure. While the authors did not see any deterioration
of right or left heart failure in their patient group, they ob-
served an impressive symptomatic benefit [11].
As our patient was an 18-year-old with a large VSD and
severe PHT, we performed a vasoreactivity test in order to
assess whether the defect could be closed. The patient’s
left heart cavities were found to be enlarged, the pulmon-
ary artery flow velocity was high and the response to the
vasoreactivity test was positive, so the patient was deemed
a suitable candidate for transcatheter closure. However, as
the patient was a young adult with bidirectional shunt and
an enlarged right ventricle and pulmonary artery, we de-
bated whether or not to fenestrate the device.
A review of literature did not reveal any cases with manu-
ally fenestrated devices used for closure of VSDs in patients
with severe PHT. However, based on the Bruch study men-
tioned above and others that used fenestrated ASOs, we
assumed that such a device in our case would allow for bi-
directional shunt and could possibly reduce PHT in the
long run. While no satisfactory reduction in pulmonary ar-
tery pressure was seen immediately after the procedure,
transthoracic ECHO performed 24 hours later showed left-
to-right gradient of 35–40 mmHg through the fenestration.
Figure 4 Nodal rhythm (top strip) on ECG and non-sustained VT attack (bottom strip) on 24-hour Holter ECG.
Figure 5 Patient ECG on day 9.
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value was the same, average aortic pressure was 75 mmHg,
average pulmonary artery pressure was 30 mmHg and
PVR/SVR was 0.2.
Both minor and major complications such as hemolysis,
cardiac perforation, device malposition, thromboembol-
ism, temporary or permanent rhythm disorders, endocar-
ditis and death may occur during, immediately after or in
the follow-up of transcatheter defect closure [4,12]. In our
case, a nodal rhythm started 12 hours after the procedure
and spontaneously reverted to normal 9 days later. Tem-
porary junctional rhythms following closure of muscular
VSDs have also been reported in the literature [12,13].
Heart block occurring after placement of an oversized
device can be attributed to the expansion of the device
against the conducting tissue. Even if the device is not
oversized, it may cause an inflammatory reaction or for-
mation of scarring in the conduction tissue, in which case
steroid therapy may be useful [14]. The nodal rhythm in
our patient can be attributed to the fact that an ASO has a
larger left disc and a narrower gap between the discs than
a VSD device, which may have put pressure on the con-
duction system or the neighboring tissues.
Conclusion
In patients with large VSDs, large ASDs may be used as
well as large muscular VSD occluders or post-myocardial
infarction muscular VSD occluders. In cases with risk of
pulmonary vascular disease, a safer option would be to
close the defect using a manually fenestrated device.
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